$37.31
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."
Overview
52-week range
$23
$43
71% of range
Avg surprise (last 2)
-26.2%
Avg reaction (last 2)
+2.6%
100% positive
Latest IV / EM
61%
EM ±3.6% · $38 · Jul 24
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-1.37 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.81 | — | — | — | — | financials |
| Wed Jul 23, 2025 | Jun/2025 | $-0.58 | $-0.44 | -31.8% | — | +4.0% | earnings |
| Wed Apr 23, 2025 | Mar/2025 | $-0.41 | $-0.34 | -20.6% | — | +1.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.22 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.20 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.26 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.23 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.19 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-164M | — | $-99M | $-75M | $-55M | — | $-37M | $-34M |
| Net income | $-158M | — | $-91M | $-66M | $-46M | — | $-25M | $-22M |
| EPS (diluted) | $-1.37 | — | $-0.81 | $-0.58 | $-0.41 | — | $-0.22 | $-0.20 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $118M | $166M | $100M | $34M | $38M | $27M | $50M | $44M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $608M | $716M | $739M | $827M | $866M | $907M | $937M | $946M |
| Total assets | $608M | $716M | $739M | $828M | $867M | $908M | $938M | $947M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $106M | $77M | $26M | $32M | $20M | $28M | $26M | $26M |
| Total equity | $502M | $639M | $713M | $795M | $847M | $880M | $911M | $921M |